The ARUP Institute for Learning is committed to supporting educational events that advance the practice of laboratory medicine and improve quality patient care by providing guest speakers at local and regional meetings. Listed below are the current events where the Institute for Learning is providing sponsored speakers.
Marc Roger Couturier, PhD, D(ABMM)
Medical Director, Microbial Immunology
Medical Director, Parasitology and Fecal Testing
Medical Director, Infectious Disease Rapid Testing
Shigatoxigenic E. coli: A Fully Emerged, Still-Underappreciated Pathogen
Shigatoxigenic E. coli (STEC) is an enteric pathogen associated with several foodborne infections throughout the world every year. The major virulence determinant that defines STEC is the shiga-like toxin which is capable of transmission between various gram-negative organisms. STEC causes significant morbidity during acute outbreaks, and can cause mortality associated with the development of hemolytic uremic syndrome. Until recently, testing for STEC in the clinical laboratory was inadequate, relying solely on selective, serogroup-biased culture methods. Recent advancements have been made which allow for toxin detection or molecular detection of toxin genes from stool specimens, removing the culture bias problem. With these improvements in screening, the cases of STEC reported have increased significantly; revealing a pathogen that may have eluded the laboratory for decades. The 2011 STEC outbreak in Germany will be discussed in detail as an example of the emerging nature of this enigmatic pathogen.
Helicobacter pylori: Update on Disease, Diagnosis and Discouraging Trends
Helicobacter pylori is one of the most common bacterial infections worldwide, with infection rates upwards of 50% of the human population. While most of these infections are asymptomatic, a significant number of patients will develop severe disease due to this bacterial pathogen, including serious life threatening gastric cancers. The testing strategy for Helicobacter pylori will be reviewed, with particular focus on the non-invasive mechanisms of testing that are central to the clinical pathology laboratory and consistent with guidelines issues by multiple professional organizations. Finally, challenges related to proper test utilization and treatment failures will be discussed.
David G. Grenache, PhD
Medical Director, Special Chemistry
Co-Medical Director, Electrophoresis/Manual Endocrinology
Section Chief, Chemistry
Screening for Gestational Diabetes Mellitus: Challenges and Controversies
Gestational diabetes mellitus (GDM) is associated with several adverse outcomes for the fetus, newborn, and mother. Evidence clearly shows that identifying and treating pregnant women with GDM ameliorates poor outcomes. There continues to be controversy regarding the most appropriate methods to screen for and diagnose GDM. This presentation will describe the controversies in GDM testing and review the current evidence regarding the various screening recommendations.
The Clinical Chemistry of Pregnancy
Normal pregnancy is associated with a multitude of physiological adaptations. Although most pregnancies progress without complications, problems can arise in the mother, fetus, or placenta. This presentation describes normal pregnancy-related physiological changes and several disorders that are associated with pregnancy that can affect laboratory test results.
David R. Hillyard, MD
Medical Director, Molecular Infectious Diseases
The Changing Landscape of Hepatitis C Testing and Therapy
The discovery, diagnosis, and treatment of the hepatitis C virus (HCV) rank as one of modern medicine’s great accomplishments. At each stage of the HCV revolution, laboratory testing has been key to foundational research, identification of chronically infected patients, and rational guidance of evolving therapies. Recent initiatives for comprehensive screening and the availability of new well-tolerated, highly effective therapies have galvanized the public’s attention as never before.
This video lecture will review the evolving role of laboratory testing in the diagnosis and management of chronic HCV infection, focusing on current guidelines and test resources. It will also address expected public health outcomes and issues in this era of the HCV cure.
Justin R. Rhees, MS, MLS(ASCP)CMSBBCM
Assistant Professor, Program Director, University of Utah
Sponsored by ARUP
Advanced Antibody Identification: Case Studies
Difficult antibody identification cases in transfusion can be more easily resolved with knowledge of blood group antigen characteristics, antibody idiosyncrasies, and established algorithms to help know which way to go. However, even with the best of these, the process can still feel a bit like falling down a rabbit hole. In this presentation, we will explore several advanced cases, and you may be a bit surprised at the end when the answer isn’t exactly what you expect.
Robert B Carpenter, MS, MT(ASCP)
Senior Healthcare Consultant
Lab Utilization Management: How to Build a Win/Win/Win/Win Program
Lab utilization management is becoming an essential tool in assisting hospitals to improve patient care, manage costs, and add value. Much of the value comes from the immediate benefits it provides to hospitals, physicians, payors, and (most importantly) patients. This session provides a template for establishing a successful UM program.
Frederick G. Strathmann, PhD, DABCC (CC, TC)
Medical Director, Toxicology
Director, High-Complexity Platforms—Mass Spectrometry
Assistant Director, ARUP Institute of Clinical & Experimental Pathology®
Fitting Linear Quadrupoles and Round Flight Tubes into the Square Clinical Laboratory: The What, Where, and Why of Clinical Mass Spectrometry with Quality Needs for Success Identified
This session will discuss clinical applications of mass spectrometry, including a highlight of the most common types of mass spectrometry used, areas of laboratory medicine where each method has found success, and comparisons of these technologies for specific applications. I’ll also touch on some old and some new challenges that face every laboratory using mass spectrometry in the clinical environment. An emphasis on quality improvements applicable to mass spectrometry and non-mass spectrometry laboratories will be included.
Jo D Fontenot MS, MT(ASCP)
Technical Vice President and Division Manager
Point-of-Care Testing: Leading the Way
Point of Care testing (POCT) continues to expand in health care systems and laboratories become a major stakeholder in these markets. The goal of POCT is to facilitate immediate test results to improve patient outcomes. Decisions to implement point of care devices within a health care network are often made without thorough consideration of the operating costs, the analytical performance, patient safety concerns, and regulatory compliance. The expertise of laboratory personnel is a vital resource to health care systems as they are often called upon to provide input on decisions regarding the implementation and use of point of care devices. This workshop is designed to help you gain the knowledge you need to be able to provide guidance to point of care testing within your institution.